NCT02923986 2020-05-28Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDSBio-Path Holdings, Inc.Phase 1/2 Withdrawn